Peptides
BPC-157, TB-500 and Retatrutide: Regulatory Status vs Marketing Claims
Regulatory status, available human evidence and online marketing claims are three different questions. Combining them produces misleading conclusions.
Why the distinction matters
Marketing pages routinely blend three separate questions: what a substance's regulatory status is, what human evidence exists for it, and what is being claimed about it. Answering all three with one sentence is how a substance under investigation becomes, in a reader's mind, an available therapy.
What the official sources state
Regulatory status of BPC-157, TB-500 and retatrutide as described by the cited FDA and ClinicalTrials.gov sources. Status is not a statement about benefit, and no substance here is presented as available therapy.
| Substance | Approval status | What the source states |
|---|---|---|
| BPC-157 | Not an FDA-approved drug | FDA identifies limited safety information and potential compounding-related risks. |
| TB-500 | Not an FDA-approved drug | FDA reports no identified human exposure data for the marketed fragment in its safety review. |
| Retatrutide | Investigational | Phase 3 research is ongoing; it is not an approved or publicly available therapy. |
What this can support
- Separating regulatory status from marketing language.
- Recognising that investigational is not the same as available.
- Checking a claim against the official source before acting on it.
What it cannot support
- Describing any of these as approved or publicly available therapy.
- Any dose, frequency, cycle length or stack.
- Sourcing or purchasing information.
- Personal recommendations or predictions of benefit.
Questions to take to a licensed clinician
- 01What is the regulatory status of what is being offered to me?
- 02What human evidence exists, and where is it published?
- 03Who is accountable for safety monitoring if something goes wrong?
The free guide explains how the system approaches decisions like these — measurement first, structure before intensity, ownership at the end.
Get the Ascendant GoodiesSources
- FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (opens in a new tab)
- ClinicalTrials.gov — study record NCT05929066 (opens in a new tab)
Sources last checked
Written by
The position
Regulatory status, evidence quality and marketing claims are three different things.
PeptidesRelated reading
This article is general education. It is not medical advice, a diagnosis or treatment guidance, and it does not recommend for or against any medication, protocol or provider. Decisions about your health belong with a qualified professional who knows your history.
Ascendant Health is a coaching service. It does not practise medicine or prescribe.